dc.contributor
Institut Català de la Salut
dc.contributor
[Giner-Soriano M, Roso-Llorach A, Morros R, Casajuana M, Bolíbar B, Violan C] Institut Universitari d'Investgació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Vedia Urgell C] Unitat de farmàcia, Servei d'Atenció Primària Barcelonès Nord i Maresme, Institut Català de la Salut, Badalona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Capellà D, Castells X] Translab Research Group, Unitat de Farmacologia Clínica, Departament de Ciències Mèdiques, Facultat de Medicina, UdG, Girona, Spain. [Ferreira-González I] Unidad de Epidemiología del Servicio de Cardiología, Hospital Vall d'Hebron y CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. [Troncoso-Mariño A] Unitat de Coordinació i Estratègia del Medicament, Institut Català de la Salut, Barcelona, Spain. [Diogène E] Servei de Farmacologia, Hospital Vall d'Hebron, Barcelona, Spain. [Elorza JM] System for the Improvement of Research in Primary Care (SIDIAP), Barcelona, Spain.
dc.contributor
IDIAP Jordi Gol
dc.contributor.author
Capellà, Dolors
dc.contributor.author
Castells Cervelló, Xavier
dc.contributor.author
Ferreira González, Ignacio
dc.contributor.author
Diogène Fadini, Eduard
dc.contributor.author
Elorza Ricart, Josep Maria
dc.contributor.author
Casajuana-Closas, Marc
dc.contributor.author
Bolíbar-Ribas, Bonaventura
dc.contributor.author
Violán-Fors, Concepción
dc.contributor.author
Troncoso Mariño, Amelia
dc.contributor.author
Morros, Rosa
dc.contributor.author
Giner-Soriano, Maria
dc.contributor.author
Roso-Llorach, Albert
dc.contributor.author
Vedia Urgell, Cristina
dc.date.accessioned
2025-10-24T10:37:23Z
dc.date.available
2025-10-24T10:37:23Z
dc.date.issued
2016-04-22T10:05:18Z
dc.date.issued
2016-04-22T10:05:18Z
dc.date.issued
2016-01-28
dc.identifier
Giner-Soriano M, Vedia-Urgell C, Roso-Llorach A, Morros R, Capellà D, Castells
X, et al. Effectiveness, safety and costs of thromboembolic prevention
in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study
and baseline characteristics of a cohort from a primary care electronic database.
BMJ Open. 2016;6(1):e010144.
dc.identifier
https://hdl.handle.net/11351/1998
dc.identifier
10.1136/bmjopen-2015-010144
dc.identifier.uri
https://hdl.handle.net/11351/1998
dc.description.abstract
atrial fibrillation, electronic health records, anticoagulants, platelet aggregation inhibitors, stroke, bleeding
dc.description.abstract
Purpose
Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke.
The main objective of ESC-FA study is to analyse the drugs used for the management of the disease in real-use conditions, in particular antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of Phase I of the ESC-FA study and the baseline characteristics of newly diagnosed patients with atrial fibrillation in Catalonia, Spain.
Participants
The data source is SIDIAP database. The population included are all patients with non-valvular atrial fibrillation diagnosis registered in the electronic health records during 2007-2012.
Findings to date
A total of 22,585 patients with non-valvular atrial fibrillation were included in the baseline description. Their mean age was 72.8 years and 51.6% were men. The most commonly prescribed antithrombotics were vitamin K antagonists (40.1% of patients) and platelet aggregation inhibitors (32.9%); 25.3% had not been prescribed antithrombotic treatment. Age, gender, comorbidities and comedication at baseline were similar to those reported for previous studies.
Future plans
The next steps in the ESC-FA study will be assessing effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes’ rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation.
dc.format
application/pdf
dc.relation
http://bmjopen.bmj.com/content/6/1/e010144.full
dc.rights
Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Atenció primària - Catalunya - Investigació
dc.subject
Fibril·lació auricular - Tractament
dc.subject
Anticoagulants (Medicina)
dc.subject
DISEASES::Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Records as Topic::Medical Records::Health Records, Personal::Electronic Health Records
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants
dc.subject
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros médicos::sistemas informatizados de historias clínicas::historias clínicas electrónicas
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes
dc.title
Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
